Abstract:Abstract BACKGROUND Metabolic dysfunction associated steatotic liver disease (MASLD) is observed in both ulcerative colitis (UC) and Crohn's disease, affecting around 27.5% of cases over an average duration of 4.6 years. However, data on the prevalence, associated predictors, and outcomes of MASLD in UC patients remains scarce. METHODS We conducted a nationwide retrospective cohort study to assess the prevalence, associated comorbidities, risk determinants, gastrointestinal complications, and hospitalization outcomes related to MASLD in UC patients. Descriptive statistics were used to summarize patient demographics and manifestations. Univariate and multivariate logistic regression models were used to evaluate the predictors and consequences of MASLD among patients with UC. RESULTS 204,966 hospital discharges diagnosed with UC were extracted, 1.8% (3,733) of the patients had MASLD (Figure 1). Compared to UC patients without MASLD, those with MASLD had a significantly prolonged median length of stay (LOS) (6 days; IQR: 3-9 vs. 4 days; IQR: 2-6, P<0.002) and higher median total charges ($69,547 vs. $65,738, P<0.05) (Table 1). Patients with Metabolic dysfunction-associated steatohepatitis (MASH) had notably increased mortality rates (4.8% vs. 2.1%, P=0.004), longer median LOS (8 vs. 6 days, P<0.001), and greater median total charges ($81,152 vs. $65,752, P<0.001) than those without MASH. UC patients with MASLD had a higher prevalence of conditions such as diabetes mellitus (28.1% vs. 19.6%, P<0.001), obesity (26.8% vs. 11.2%, P<0.001), metabolic syndrome (0.7% vs. 0.1%, P<0.001), dyslipidemia (33.2% vs. 28.6%, P<0.001), and vitamin D deficiency (4.1% vs. 2.7%, P<0.001). They also had a higher prevalence of ulcerative pancolitis (22.9% vs. 15.3%, P<0.001) and left-sided colitis (6.8% vs. 4.1%, P<0.001). Conditions such as metabolic syndrome (OR: 3.36; 95% CI: 2.25 – 5.50, P<0.001), abnormal liver function tests (OR: 3.00; 95% CI: 2.01 - 4.48, P<0.001), obesity (OR: 2.51; 95% CI: 2.33 - 2.72, P<0.001), diabetes mellitus (OR: 1.32; 95% CI: 1.22 - 1.43, P<0.001), vitamin D deficiency (OR: 1.40; 95% CI: 1.18 - 1.64, P<0.001), ulcerative pancolitis (OR: 1.64; 95% CI: 1.51 - 1.78, P<0.001), dyslipidemia (OR: 1.27; 95% CI: 1.18 - 1.38, P<0.01), gallstone disease (OR: 3.75; 95% CI: 3.16 - 4.45, P<0.001), chronic pancreatitis (OR: 3.20; 95% CI: 2.65 - 3.88, P<0.001), thrombocytopenia (OR: 1.60; 95% CI: 1.41 - 2.81, P<0.001), and the age group 45-64 (OR: 1.31; 95% CI: 1.20-1.42, P<0.001) were significant positive predictors for MASLD in UC patients. CONCLUSIONS MASLD is a common comorbidity in UC patients and significantly influences both morbidity and mortality. We identified multiple positive predictors of MASLD in patients with UC, and further studies are needed to study early detection and improve long-term outcomes among UC patients.

PREVALENCE AND PREDICTORS OF METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE IN A RETROSPECTIVE COHORT OF PATIENTS WITH ULCERATIVE COLITIS

Dietary macro and micronutrients associated with MASLD: Analysis of a national US cohort database

Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients with Inflammatory Bowel Diseases: A Pilot Study

Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease Is Independently Associated With Reduced Renal Function

Association between MASLD and increased risk of serious bacterial infections requiring hospital admission: A meta-analysis

Advanced Liver Fibrosis Predicts Liver Outcomes in Biopsy-proven Metabolic Dysfunction-associated Steatotic Liver Disease: A U.S.-based Single-center Retrospective Cohort Study

Metabolic Dysfunction‐Associated Steatotic Liver Disease Increases the Risk of Severe Infection: A Population‐Based Cohort Study

Metabolic Dysfunction-Associated Steatotic Liver Disease and All-Cause and Cause-Specific Mortality

Epidemiology of Metabolic Dysfunction-Associated Steatotic Liver Disease

Increased risk of chronic kidney disease and mortality in a cohort of people diagnosed with metabolic dysfunction associated steatotic liver disease with hepatic fibrosis

Long‐term risk of cardiovascular disease associated with MASLD and different cardiometabolic risk factors in IBD patients: A prospective cohort study

Metabolic syndrome traits differentially and cumulatively influence micro- and macrovascular disease risk in patients with MASLD

Prevalence and prognosis of patients with MASLD-related cirrhosis after an ICU hospitalization in France: A single-centre prospective study

The association of metabolic dysfunction-associated steatotic liver disease (MASLD) with the risk of myocardial infarction: a systematic review and meta-analysis

Socioeconomic factors associated with the presence of and outcomes in metabolic dysfunction-associated steatotic liver disease

Prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in a middle-aged population with overweight and normal liver enzymes, and diagnostic accuracy of noninvasive proxies

S2018 Lean Metabolic Dysfunction-Associated Steatotic Liver Disease: Higher Mortality and Complication Rates Compared to Higher BMI

Prevalence, proportions of elevated liver enzyme levels, and long‐term cardiometabolic mortality of patients with metabolic dysfunction‐associated steatotic liver disease

MASLD: a systemic metabolic disorder with cardiovascular and malignant complications

Patient-Reported Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease

Clinical features and mortality outcomes of patients with MASLD only compared to those with MAFLD and MASLD